INKT — MiNK Therapeutics, Inc.

Summary of MiNK Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended 2025 with a cash balance of $13.4 million, up from $4.6 million in 2024. Raised an additional $3 million post-year-end.
• Net Loss: Q4 2025 net loss was $2.6 million ($0.56 per share), compared to $2.5 million ($0.62 per share) in Q4 2024. Full-year net loss was $12.5 million ($2.93 per share), up from $10.8 million ($2.86 per share) in 2024.
• Operating Costs: Decreased nearly 40% year-over-year, reflecting disciplined spending while advancing clinical programs.

2. Strategic Updates and Business Highlights

• Clinical Trials: MiNK is advancing its allogeneic invariant natural killer T cell (iNKT) platform with ongoing Phase II trials in solid tumors, graft-versus-host disease (GvHD), and severe hypoxemic pneumonia (ARDS).
• Clinical Efficacy: In cancer trials, patients showed median overall survival exceeding 23 months and complete remissions beyond 2 years. In ARDS, treated patients demonstrated prolonged survival and improved lung function.
• Funding: Secured non-dilutive funding from NIH and philanthropic sources to support clinical trials, particularly for GvHD and a PRAME-targeting iNKT program.
• Partnerships: Engaged in collaborations to enhance research and development without diluting shareholder equity.

3. Forward Guidance and Outlook

• Upcoming Milestones: Plans to initiate a randomized Phase II/III study for ARDS and GvHD trials in the first half of 2026, with initial clinical data expected in the second half of the year.
• Scientific Validation: Continued focus on generating data through presentations and publications to support clinical advancement and regulatory pathways.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: Although operational costs decreased, the overall net loss increased, indicating ongoing financial strain as the company invests heavily in clinical trials.
• Regulatory Risks: The success of upcoming trials and the potential for regulatory approval remains uncertain, particularly in competitive therapeutic areas with no approved therapies currently available for ARDS.
• Market Competition: The company faces competition from other therapies and technologies in the cell therapy space, which could impact its market position.

5. Notable Q&A Insights

• Patient Population for Trials: The ARDS trial will include patients based on specific oxygenation criteria, with a control arm consisting of standard care. The company aims to demonstrate the efficacy of its cells in a population with no approved therapies.
• IPF and GvHD Development: The company is exploring the potential of its iNKT cells in idiopathic pulmonary fibrosis (IPF) and GvHD, with plans for separate trials and careful funding strategies.
• IL-15 Combination Trials: Clarified that MiNK has not publicly announced any collaborations involving IL-15 superagonists, emphasizing that any strategic partnerships will be disclosed when appropriate.

Overall, MiNK Therapeutics is making significant strides in its clinical programs while managing to improve its cash position and reduce operational costs. However, the company faces challenges related to increasing losses and competitive pressures in the biotechnology landscape.